2023
Hydroxychloroquine in Stage 1 Type 1 Diabetes.
Libman I, Bingley P, Becker D, Buckner J, DiMeglio L, Gitelman S, Greenbaum C, Haller M, Ismail H, Krischer J, Moore W, Moran A, Muir A, Raman V, Steck A, Toledo F, Wentworth J, Wherrett D, White P, You L, Herold K, Steck A, Greenbaum C, Lord S, Monzavi R, Katz L, Goland R, Muir A, Apperson E, DiMeglio L, Cummings E, Weinstock R, Gaglia J, Campbell F, Cabrera S, Nakhle S, English P, Huynh T, Liljenquist D, Moudiotis C, Duke S, Bosi E, Griffin K, Borg H, Lernmark A, Flynn D, Wilson D, Craig M, Moore W, Wherrett D, Tatovich D, Gitelman S, Philipson L, Haller M, Knip M, Tsalikian E, Baidal D, Thomas I, Moran A, Libman I, White P, Raman V, Raleigh Z, Solorzano C, Rodriguez H, Russell W, So M, Colman P, Couper J, Sherr J. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care 2023, 46: 2035-2043. PMID: 37708415, PMCID: PMC10620539, DOI: 10.2337/dc23-1096.Peer-Reviewed Original ResearchConceptsAnnual ophthalmologic examinationsMedian Follow-UpStage 1 diseaseHydroxychloroquine armPreplanned secondary analysisAutoantibodies to GADData Safety Monitoring BoardAnti-insulin autoantibodiesSafety monitoring boardType 1 diabetesInnate immune responseOphthalmologic examinationPositive autoantibodiesAnti-GADHydroxychloroquine treatmentMonth 6Oral glucoseFollow-upDrug treatmentImmune responseHydroxychloroquineAutoantibodiesTransient decreaseMonitoring boardReduced titersCell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and can be reversed by hydroxychloroquine
León-Martínez D, Lynn T, Abrahams V. Cell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and can be reversed by hydroxychloroquine. Journal Of Reproductive Immunology 2023, 157: 103945. PMID: 37062109, DOI: 10.1016/j.jri.2023.103945.Peer-Reviewed Original ResearchConceptsToll-like receptor 9Aspirin-triggered lipoxinsODN 2216Pathogenesis of preeclampsiaTLR9-dependent mannerNovel therapeutic approachesTrophoblast cell modelReceptor 9CpG oligodeoxynucleotideTLR9 inhibitorPlacental functionTherapeutic approachesCell-free fetal DNACpG motifsTherapeutic agentsHCQPreeclampsiaHydroxychloroquineFetal DNACell viabilityCffDNAMolecular underpinningsCell modelInhibitionASA
2021
Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic
Heldman MR, Kates OS, Safa K, Kotton CN, Georgia SJ, Steinbrink JM, Alexander BD, Hemmersbach‐Miller M, Blumberg EA, Multani A, Haydel B, La Hoz RM, Moni L, Condor Y, Flores S, Munoz CG, Guitierrez J, Diaz EI, Diaz D, Vianna R, Guerra G, Loebe M, Rakita RM, Malinis M, Azar MM, Hemmige V, McCort ME, Chaudhry ZS, Singh PP, Kramer K, Velioglu A, Yabu JM, Morillis JA, Mehta SA, Tanna SD, Ison MG, Derenge AC, van Duin D, Maximin A, Gilbert C, Goldman JD, Lease ED, Fisher CE, Limaye AP, Team T. Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. American Journal Of Transplantation 2021, 22: 279-288. PMID: 34514710, PMCID: PMC8653312, DOI: 10.1111/ajt.16840.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsTransplant recipientsCOVID-19IL-6/ILComorbidity-adjusted mortalityUse of corticosteroidsUse of hydroxychloroquineMultivariable logistic regressionBaseline comorbiditiesMulticenter registryImproved survivalReceptor inhibitorsGeneral populationMortality trendsMortalityLogistic regressionFurther studiesLater periodRecipientsCorticosteroidsComorbiditiesHydroxychloroquinePandemicPatientsEvaluating the risk of QTc prolongation associated with hydroxychloroquine use with antidepressants in lupus patients with fibromyalgia
Renaldi J, Koumpouras F, Dong X. Evaluating the risk of QTc prolongation associated with hydroxychloroquine use with antidepressants in lupus patients with fibromyalgia. Lupus 2021, 30: 1844-1848. PMID: 34353174, DOI: 10.1177/09612033211034562.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusQTc prolongationHCQ useLupus patientsQTc intervalFibromyalgia syndromeDose of hydroxychloroquineLethal ventricular arrhythmiasMild QTc prolongationElectronic medical recordsHydroxychloroquine useLupus erythematosusVentricular arrhythmiasMedical recordsBazett's formulaCardiological conditionsOverall prolongationSudden deathHydroxychloroquineImmunomodulatory propertiesAntidepressantsPatientsDrug useConcurrent useECG monitoringRepeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry
Bradley SM, Emmons-Bell S, Mutharasan RK, Rodriguez F, Gupta D, Roth G, Gluckman TJ, Shah RU, Wang TY, Khera R, Peterson PN, Das S. Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry. Scientific Reports 2021, 11: 15097. PMID: 34302004, PMCID: PMC8302649, DOI: 10.1038/s41598-021-94203-7.Peer-Reviewed Original ResearchConceptsCOVID-19Use of hydroxychloroquineActive COVID-19Cross-sectional analysisRandomized trialsIneffective therapyNational registryMedian useClinical careClinical informationDeimplementationU.S. hospitalsOverall proportionLittle dataHydroxychloroquineFurther studiesPatientsRegistryTherapyHospitalTrialsCarePharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans
Gerlovin H, Posner DC, Ho YL, Rentsch CT, Tate JP, King JT, Kurgansky KE, Danciu I, Costa L, Linares FA, Goethert ID, Jacobson DA, Freiberg MS, Begoli E, Muralidhar S, Ramoni RB, Tourassi G, Gaziano JM, Justice AC, Gagnon DR, Cho K. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. American Journal Of Epidemiology 2021, 190: 2405-2419. PMID: 34165150, PMCID: PMC8384407, DOI: 10.1093/aje/kwab183.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Bacterial AgentsAzithromycinCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationFemaleHospitalizationHumansHydroxychloroquineIntention to Treat AnalysisMachine LearningMaleMiddle AgedPharmacoepidemiologyRetrospective StudiesSARS-CoV-2Treatment OutcomeUnited StatesVeteransConceptsUS veteransCOVID-19Veterans Affairs Health Care SystemRecent randomized clinical trialsAdministration of hydroxychloroquineEffectiveness of hydroxychloroquineRisk of intubationEffect of hydroxychloroquineElectronic health record dataRandomized clinical trialsTreatment of patientsUS veteran populationCOVID-19 outcomesCoronavirus disease 2019Health record dataRigorous study designsHealth care systemSurvival benefitTreat analysisEarly therapyHospitalized populationClinical trialsObservational studyDisease 2019HydroxychloroquineCOVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients
Stewart M, Rodriguez-Watson C, Albayrak A, Asubonteng J, Belli A, Brown T, Cho K, Das R, Eldridge E, Gatto N, Gelman A, Gerlovin H, Goldberg SL, Hansen E, Hirsch J, Ho YL, Ip A, Izano M, Jones J, Justice AC, Klesh R, Kuranz S, Lam C, Mao Q, Mataraso S, Mera R, Posner DC, Rassen JA, Siefkas A, Schrag A, Tourassi G, Weckstein A, Wolf F, Bhat A, Winckler S, Sigal EV, Allen J. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. PLOS ONE 2021, 16: e0248128. PMID: 33730088, PMCID: PMC7968637, DOI: 10.1371/journal.pone.0248128.Peer-Reviewed Original ResearchConceptsHospitalized COVID-19 patientsCOVID-19 patientsUse of hydroxychloroquineElectronic health recordsAdverse eventsTreatment groupsCOVID-19Administration of hydroxychloroquineReagan-Udall FoundationProportional hazards modelHealth systems researchHospitalized patientsElevated riskPropensity score methodsHazards modelHydroxychloroquinePatientsSignificant global threatPharmaceutical interventionsAzithromycinHealth recordsMortalityCOVID-19 pandemicCancer researchTreatment
2020
Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19
Sattui S, Liew J, Graef E, Coler-Reilly A, Berenbaum F, Duarte-García A, Harrison C, Konig M, Korsten P, Putman M, Robinson P, Sirotich E, Ugarte-Gil M, Webb K, Young K, Kim A, Sparks J. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Review Of Clinical Immunology 2020, 16: 659-666. PMID: 32620062, PMCID: PMC7594186, DOI: 10.1080/1744666x.2020.1792778.Peer-Reviewed Original ResearchIncidence and determinants of QT interval prolongation in COVID‐19 patients treated with hydroxychloroquine and azithromycin
Maraj I, Hummel JP, Taoutel R, Chamoun R, Workman V, Li C, Tran L, DelVecchio A, Howes C, Akar JG. Incidence and determinants of QT interval prolongation in COVID‐19 patients treated with hydroxychloroquine and azithromycin. Journal Of Cardiovascular Electrophysiology 2020, 31: 1904-1907. PMID: 32485061, PMCID: PMC7300464, DOI: 10.1111/jce.14594.Peer-Reviewed Original ResearchEarly Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis
Risch HA. Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis. American Journal Of Epidemiology 2020, 189: 1218-1226. PMID: 32458969, PMCID: PMC7546206, DOI: 10.1093/aje/kwaa093.Peer-Reviewed Original ResearchConceptsOutpatient treatmentHigh-risk COVID-19 patientsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2High-risk patientsUse of hydroxychloroquineMultiple comorbid conditionsCOVID-19 patientsEfficacy of hydroxychloroquineEarly outpatient treatmentStandard of careSyndrome coronavirus 2Mild effectivenessOutpatient diseasesOutpatient illnessOutpatient trialSuch patientsSymptomatic diseaseComorbid conditionsCoronavirus 2Hospitalized inpatientsClinical trialsCandidate medicationsHydroxychloroquine
2019
New Applications of Old Drugs as Novel Therapies in Idiopathic Pulmonary Fibrosis. Metformin, Hydroxychloroquine, and Thyroid Hormone
Manning EP, Losier A, Emeagwali N, Ryu C, Honiden S. New Applications of Old Drugs as Novel Therapies in Idiopathic Pulmonary Fibrosis. Metformin, Hydroxychloroquine, and Thyroid Hormone. American Journal Of Respiratory And Critical Care Medicine 2019, 199: 1561-1563. PMID: 30822095, PMCID: PMC7051474, DOI: 10.1164/rccm.201809-1700rr.Peer-Reviewed Original Research
2016
50LB Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection
Kroon E, Ananworanich J, Le L, Intasan J, Benjapornpong K, Pinyakorn S, Karnsomlap P, Tipsuk S, Rattanamanee S, Hellmuth J, Eamyoung P, Eubanks K, Yang H, Phanuphak N, Souza M, Valcour V, Spudich S, Groups S. 50LB Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection. Journal Of Virus Eradication 2016, 2: 27. DOI: 10.1016/s2055-6640(20)30995-x.Peer-Reviewed Original Research
2014
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).
Neal J, Wakelee H, Feliciano J, Goldberg S, Morgensztern D, Das M, Heist R, Lennes I, Muzikansky A, Edelman M, Gettinger S, Sequist L. A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8088-8088. DOI: 10.1200/jco.2014.32.15_suppl.8088.Peer-Reviewed Original Research
2011
Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression
Wu XX, Guller S, Rand JH. Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. American Journal Of Obstetrics And Gynecology 2011, 205: 576.e7-576.e14. PMID: 21871597, PMCID: PMC3224185, DOI: 10.1016/j.ajog.2011.06.064.Peer-Reviewed Original ResearchConceptsAntiphospholipid antibodiesHuman placental syncytiotrophoblastPlacental syncytiotrophoblastAnnexin A5 anticoagulant shieldA5 expressionEffect of hydroxychloroquineAnnexin A5 expressionFirst morphologic evidenceAntibody-mediated disruptionAntiphospholipid syndromeComputer-based morphometric analysisThrombogenic mechanismsBeWo trophoblastsImmune complexesNovel treatmentsHydroxychloroquineAntimalarial drugsImmunoglobulin G (IgG) bindingMorphologic evidenceSyncytiotrophoblastImmunoglobulin GsPrimary culturesAntibodiesAnnexin A5Laser confocal microscopy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply